Press release
Secondary Hyperparathyroidism Market Growth, Trends, Consumer Demand and Key Opportunities
Secondary Hyperparathyroidism Market
Secondary hyperparathyroidism (SHPT) is a frequent and serious complication of chronic kidney disease (CKD), characterized by excessive secretion of parathyroid hormone (PTH) due to impaired calcium, phosphorus, and vitamin D metabolism. Left untreated, SHPT leads to mineral and bone disorders, cardiovascular complications, and poor quality of life for patients.
With the global CKD population rising sharply, particularly among patients on dialysis, the SHPT market has gained significant importance. Treatment approaches have traditionally included vitamin D analogs, phosphate binders, and calcimimetics. However, the market is now being reshaped by next-generation calcimimetics, extended-release formulations, and novel biologics that offer improved efficacy and tolerability. Between 2024 and 2034, the SHPT market is projected to grow steadily, driven by rising awareness, broader screening programs, and the integration of innovative treatment solutions.
Download Full PDF Sample Copy of Market Report @
https://exactitudeconsultancy.com/request-sample/72046
Market Overview
• Market Size 2024: USD 6.4 billion (estimated)
• Forecasted Market Size 2034: USD 11.8 billion
• CAGR (2024-2034): 6.3%
Key Highlights
• SHPT prevalence continues to grow in line with CKD and dialysis patient populations.
• Strong adoption of calcimimetics such as cinacalcet and etelcalcetide, alongside vitamin D analogs.
• Expanding pipeline of oral therapies, biologics, and combination approaches.
• Government initiatives and reimbursement frameworks supporting CKD and SHPT management.
Segmentation Analysis
By Product
• Calcimimetics (cinacalcet, etelcalcetide, evocalcet)
• Vitamin D analogs (calcitriol, paricalcitol, alfacalcidol)
• Phosphate binders
• Combination therapies
• Pipeline biologics and gene-targeted therapies
By Platform
• Hospital pharmacies
• Retail pharmacies
• Online pharmacies
By Technology
• Pharmacological therapies (oral and injectable)
• Biologics and targeted therapies
• Gene-based and regenerative approaches (pipeline)
• Combination therapy models
By End Use
• Hospitals and dialysis centers
• Specialty nephrology clinics
• Homecare and outpatient facilities
By Application
• SHPT in pre-dialysis CKD
• SHPT in dialysis patients (hemodialysis and peritoneal dialysis)
• Post-transplant SHPT
Summary:
Segmentation shows that calcimimetics dominate current treatment, but the vitamin D analogs segment remains critical for comprehensive SHPT management. Emerging biologics and extended-release oral therapies are expected to capture market share over the forecast period.
Explore Full Report here:
https://exactitudeconsultancy.com/reports/72046/secondary-hyperparathyroidism-market
Regional Analysis
North America
• Largest market share in 2024, supported by high CKD prevalence, advanced dialysis infrastructure, and strong reimbursement policies.
• The U.S. leads due to broad adoption of calcimimetics and extensive clinical research activity.
Europe
• Significant use of vitamin D analogs and calcimimetics in Germany, France, and the UK.
• Favorable healthcare systems and rare disease frameworks enhancing treatment uptake.
Asia-Pacific
• Fastest-growing region (CAGR ~7.5%), with large dialysis populations in China, India, and Japan.
• Expanding healthcare investments and CKD screening programs driving demand.
Middle East & Africa
• Growing CKD burden but limited access to advanced SHPT therapies.
• International collaborations improving drug access in select regions.
Latin America
• Brazil and Mexico emerging as strong markets with government-backed kidney health initiatives.
• Increasing partnerships with multinational pharma firms expanding treatment availability.
Summary:
North America leads the market, but Asia-Pacific is expected to deliver the fastest growth, reflecting demographic trends and growing healthcare infrastructure.
Market Dynamics
Key Growth Drivers
• Rising prevalence of CKD and dialysis patients, the primary risk group for SHPT.
• Expanding adoption of calcimimetics and vitamin D analogs.
• Strong research pipelines for novel biologics and oral therapies.
• Supportive government initiatives promoting CKD care.
Key Challenges
• High treatment costs, particularly for calcimimetics and biologics.
• Adherence issues due to pill burden and side effects.
• Limited awareness and screening in low-income countries.
• Donor shortages affecting CKD transplantation and SHPT resolution.
Latest Trends
• Development of second-generation calcimimetics (etelcalcetide, evocalcet) with better tolerability.
• Increasing use of combination therapies for optimal calcium-phosphate balance.
• Growing adoption of extended-release oral formulations for patient convenience.
• Research into gene-targeted and regenerative therapies for long-term disease modification.
Get Your Exclusive Offer with up to 10% Discount :
https://exactitudeconsultancy.com/checkout/?currency=USD&type=single_user_license&report_id=72046
Competitor Analysis
Major Players
• Amgen Inc. (Sensipar - cinacalcet; Parsabiv - etelcalcetide)
• Kissei Pharmaceutical Co., Ltd. (Evocalcet)
• AbbVie Inc. (paricalcitol - Zemplar)
• Hoffmann-La Roche AG
• Sanofi S.A.
• Novartis AG
• Takeda Pharmaceutical Company Ltd.
• Bayer AG
• Otsuka Pharmaceutical Co., Ltd.
• Fresenius Medical Care
Summary:
The SHPT market is moderately consolidated, with Amgen holding a strong position through its calcimimetic portfolio, while companies like AbbVie and Kissei focus on vitamin D analogs and next-generation agents. Innovation is being driven by pipeline biologics and gene-targeted research, alongside strategic collaborations.
Conclusion
The secondary hyperparathyroidism market is set for strong growth, projected to reach USD 11.8 billion by 2034 at a CAGR of 6.3%. Rising CKD prevalence, growing dialysis populations, and innovations in pharmacological and biologic therapies will continue to shape the market.
Key Takeaways:
• North America dominates, but Asia-Pacific will post the fastest growth.
• Calcimimetics and vitamin D analogs remain central to treatment, with biologics expanding the pipeline.
• Dialysis centers remain critical hubs for SHPT management worldwide.
• Competitive dynamics are led by Amgen, AbbVie, and Kissei, with new entrants exploring targeted and regenerative therapies.
This report is also available in the following languages : Japanese (二次性副甲状腺機能亢進症市場), Korean (이차성 부갑상선기능항진증 시장), Chinese (继发性甲状旁腺功能亢进症市场), French (Marché de l'hyperparathyroïdie secondaire), German (Markt für sekundären Hyperparathyreoidismus), and Italian (Mercato dell'iperparatiroidismo secondario), etc.
Request for a sample of this research report at (Use Corporate Mail ID for Quick Response) @
https://exactitudeconsultancy.com/request-sample/72046
Our More Reports:
West Syndrome Market
https://exactitudeconsultancy.com/reports/72082/west-syndrome-market
Complex Regional Pain Syndrome Market
https://exactitudeconsultancy.com/reports/72084/complex-regional-pain-syndrome-market
Traumatic Brain Injury Market
https://exactitudeconsultancy.com/reports/72086/traumatic-brain-injury-market
About Us
Exactitude Consultancy is a market research & consulting services firm which helps its client to address their most pressing strategic and business challenges. Our market research helps clients to address critical business challenges and also helps make optimized business decisions with our fact-based research insights, market intelligence, and accurate data.
https://bulletin.exactitudeconsultancy.com/
https://www.thehealthanalytics.com/
https://www.analytica.global/
https://www.marketintelligencedata.com/
https://www.marketinsightsreports.com/
https://exactitudeconsultancy.com/
Connect Us:
Irfan Tamboli
PHONE NUMBER +1 (704) 266-3234
EMAIL ADDRESS: sales@exactitudeconsultancy.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Secondary Hyperparathyroidism Market Growth, Trends, Consumer Demand and Key Opportunities here
News-ID: 4188323 • Views: …
More Releases from Exactitude Consultancy
Somatotropin Deficiency Market Growth, Applications, Innovations and Business Ou …
Introduction
Somatotropin deficiency, commonly referred to as growth hormone deficiency (GHD), is a rare endocrine disorder characterized by inadequate secretion of growth hormone (GH) from the pituitary gland. It manifests in children as stunted growth and delayed development, and in adults as metabolic issues, decreased bone density, and reduced quality of life. While congenital cases are often diagnosed in childhood, acquired forms may arise later in life due to trauma, tumors,…
Endogenous Cushing's Syndrome Market to Reach USD 1.9 Billion by 2034
Endogenous Cushing's Syndrome (CS) is a rare but serious endocrine disorder caused by chronic exposure to elevated cortisol levels due to the body's own overproduction. Unlike exogenous cases induced by prolonged corticosteroid therapy, endogenous Cushing's syndrome arises from pituitary adenomas (Cushing's disease), adrenal tumors, or ectopic ACTH secretion. The condition is associated with significant morbidity-ranging from diabetes and hypertension to osteoporosis and cardiovascular complications-making early diagnosis and effective treatment critical.
Download…
Familial Amyloid Polyneuropathy (FAP) Market to Reach USD 2.4 Billion by 2034
Familial Amyloid Polyneuropathy (FAP) is a progressive, inherited rare disease caused by mutations in the transthyretin (TTR) gene, leading to the buildup of misfolded amyloid proteins in the peripheral nerves and multiple organs. This buildup causes nerve damage, autonomic dysfunction, and multi-system complications that, without treatment, can become life-threatening.
Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/72015
In recent years, FAP has emerged as a critical focus area in the…
Renal Insufficiency Market Insights and Future Outlook
Introduction
Renal insufficiency, also referred to as chronic kidney disease (CKD) or kidney function decline, is a progressive condition where the kidneys fail to filter blood effectively. It represents a major public health issue, often linked with diabetes, hypertension, obesity, and cardiovascular disease. According to global estimates, hundreds of millions of people live with some form of renal insufficiency, with many cases undiagnosed until advanced stages.
The rising prevalence of lifestyle-related disorders,…
More Releases for SHPT
US Secondary Hyperparathyroidism Treatment (SHPT) Market is growing at a CAGR of …
In recent years, the US Secondary Hyperparathyroidism Treatment (SHPT) Market has witnessed a dynamic shift, influenced by changing consumer preferences, technological advancements, and a growing emphasis on sustainability. The Research report on US Secondary Hyperparathyroidism Treatment (SHPT) Market presents a complete judgment of the market through strategic insights on future trends, growth factors, supplier landscape, demand landscape, Y-o-Y growth rate, CAGR, pricing analysis. It also provides and a lot of…
US Secondary Hyperparathyroidism Treatment (SHPT) Market Size: Set to Reach USD …
In recent years, the global US Secondary Hyperparathyroidism Treatment (SHPT) Market has witnessed a dynamic shift, influenced by changing consumer preferences, technological advancements, and a growing emphasis on sustainability. The Research report on US Secondary Hyperparathyroidism Treatment (SHPT) Market presents a complete judgment of the market through strategic insights on future trends, growth factors, supplier landscape, demand landscape, Y-o-Y growth rate, CAGR, pricing analysis. It also provides and a lot…
Secondary Hyperparathyroidism (SHPT) Treatment Market Insights, Forecast to 2030
The report extensively examines the global Secondary Hyperparathyroidism (SHPT) Treatment market while focusing on the leading companies and their business strategies, geographical growth, market segmentation, competitive environment, production, price, and cost structures. Each section of the research report has been carefully designed to examine important facets of the global market for Secondary Hyperparathyroidism (SHPT) Treatment . For instance, the market dynamics section delves deeply into the trends, opportunities, and drivers…
Secondary Hyperparathyroidism (SHPT) Treatment Market demand will reach a value …
Newark, New Castle, USA - Growth Plus Reports has published a comprehensive research report of the Secondary Hyperparathyroidism (SHPT) Treatment Market, which include a detailed study of the product offerings, advancements, applications, benefits, and scope. The report covers significant strategic developments in addition to R&D, launches of new products, acquisitions and mergers, partnerships, alliances, agreements, limited partnerships, and the regional growth of fundamental competitors operating at the global and…
Secondary Hyperparathyroidism (SHPT) Treatment Market Statistical Forecast, Trad …
Newark, New Castle, USA - Growth Plus Reports has published a new report on Secondary Hyperparathyroidism (SHPT) Treatment, which includes a detailed analysis based on competitors and important market segments (2022-2030). The Global Secondary Hyperparathyroidism (SHPT) Treatment provides a thorough analysis of many segments such as opportunities, market size, developments, innovation, sales, and overall growth of leading players. The research is based on primary and secondary statistical data, and it…
(2022 - 2030) Secondary Hyperparathyroidism (SHPT) Treatment Market Insights, Fo …
A recent market research report added to repository of Growth Plus Reports is an in-depth analysis of global Secondary Hyperparathyroidism (SHPT) Treatment Market . On the basis of historic growth analysis and current scenario of Secondary Hyperparathyroidism (SHPT) Treatment Market place, the report intends to offer actionable insights on global market growth projections. Authenticated data presented in report is based on findings of extensive primary and secondary research.…
